Neutrophil Elastase Binding Antibodies for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for binding to neutrophil elastase (NE) polypeptides, which contribute to both cancer and inflammatory conditions by promoting tumor proliferation and inflammation, and there is a need for specific molecules that can inhibit protease activity and cell uptake of NE.
Innovation Solution
Development of antibodies, antigen binding fragments, and antibody domains that specifically bind to NE polypeptides, inhibiting their protease activity and preventing cell uptake, using engineered CDRs and framework regions to create binders such as Fab and VH domains that target human NE polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neutrophil elastase (NE) polypeptides are left unbound, then tumor proliferation and inflammatory conditions are promoted, but no effective treatment mechanism exists
Solution Approach 1:
The patent introduces binder molecules (antibodies, antigen binding fragments, or antibody domains) as intermediary substances that specifically bind to NE polypeptides. These binders act as mediators between the harmful NE polypeptides and the body's defense mechanisms, blocking NE's interaction with target cells and thereby preventing tumor proliferation and inflammatory conditions without directly eliminating NE.
Solution Approach 2:
The patent extracts the harmful protease activity and cell uptake capability of NE polypeptides through specific binding. By using binders that target specific epitopes on NE, the harmful functions are separated from the NE molecule itself, allowing NE to be neutralized while preserving the binders for therapeutic use.
2Reliability
If binders are designed to specifically bind NE polypeptides, then protease activity and cell uptake are inhibited, but molecular complexity increases
Solution Approach 1:
The patent segments the binder into functional components: variable regions (VH and VL) responsible for specific NE binding, and constant regions (Fc) providing effector functions. This segmentation allows independent optimization of binding specificity (through CDRs) and functional activity (through Fc region engineering), reducing overall design complexity while maintaining high specificity.
Solution Approach 2:
The patent applies local quality by concentrating binding specificity in the complementarity-determining regions (CDRs) of the variable domains, while the constant regions provide uniform effector functions. This localization allows the CDRs to be optimized for NE specificity without compromising the functional properties of the entire binder molecule.
3Object-affected harmful factors
If binders are used to inhibit NE protease activity, then harmful effects are reduced, but manufacturing and administration complexity increases
Solution Approach 1:
The patent employs recombinant DNA technology to produce binders in microbial or mammalian cell systems, creating a scalable manufacturing process. The binders can be produced as standardized therapeutic products with controlled quality, and their half-life in circulation is optimized to provide sustained NE inhibition without requiring continuous administration, simplifying the treatment protocol.
Data Source
AI summary
This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) to an NE polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, and/or antibody domains) that bind to an NE polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer and/or an inflammatory condition are provided.